Clinical Trial Update: First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Pancreas
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Metastatic Pancreatic Cancer, Adenocarcinoma of the Pancreas | Phase 2 | Status: COMPLETED